T 705 (Synonyms: Favilavir, Favipiravir) |
| Catalog No.GC12350 |
T 705 (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, T 705-ribofuranosyl-5′-triphosphate (RTP).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 259793-96-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Favipiravir (T-705) is a novel viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with IC50 of 341 nM.
Favipiravir (T 705) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. Favipiravir (T 705) is a novel antiviral compound that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRP) of influenza and many other RNA viruses. Favipiravir-RTP does not inhibit the human DNA polymerase α, β or γ with IC50>1 mM. The IC50 for the human RNA polymerase II is 905 μM; Favipiravir is therefore 2,650 times more selective for the influenza virus RdRP, consistent with the lack of inhibition of host-cell DNA and RNA synthesis[1]. Favipiravir (T 705) acts as a pro-drug, its cytotoxicity is expected to be cell-line dependent. Favipiravir inhibits in a dose-dependent manner MNV-induced CPE (EC50: 250±11 μM) and MNV RNA synthesis in cell culture (EC50:124±42 μM). Despite this rather modest antiviral activity, Favipiravir (T 705) is able to completely inhibit norovirus replication at a concentration of 100 μg/mL, which is a concentration that has little or no adverse effect on the host cell (cell viability >80%)[2].
Favipiravir (T 705) (30 mg/kg/day, orally) improves survival compare to placebo. Favipiravir (T 705) also provides significant protection against the A/Duck/MN/1525/81(H5N1) virus at a dose of 33 mg/kg/day or more, regardless of the number of daily doses. When given 4 times a day, all mice survive[1].
Reference:
[1]. Furuta Y, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446-54.
[2]. Rocha-Pereira J, et al. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun. 2012 Aug 10;424(4):777-80.
Cell experiment: | The antiviral activity of Favipiravir (T 705) is determined using an MTS-based CPE reduction assay in the MNV/RAW 264.7 cell line. To this end, RAW 264.7 cells are seeded (1×104 cells/well) in 96-well plates and infected with MNV at an MOI of 0,001 in the presence (or absence) of a dilution series of Favipiravir (T 705) (3.13-200 μg/mL). Following 3 days of incubation, i.e. until complete CPE is observed in infected untreated cells, cell culture supernatants are collected for quantification of viral RNA load by quantitative RT-PCR (qRT-PCR). For the MTS reduction assay an MTS/Phenazine methosulphate (PMS) stock solution (2 mg/mL MTS and 46 g/mL PMS in PBS at pH 6-6.5) is diluted 1/20 in MEM. To each well, 75 μL of MTS/PMS solution is added and the optical density (OD) is read at 498 nm 2 h later. The % CPE reduction is calculated as [(ODtreated)MNW−ODVC]/[ODCC-ODVC]×100, where ODCC represents the OD of the uninfected untreated cells, whereas ODVC and (ODtreated)CC represent the OD of infected untreated cells and virus-infected cells treated with a compound concentration, respectively. The EC50 is defined as the compound concentration that protected 50% of cells from virus-induced CPE. Adverse effects of the molecule on the host cell are also assessed by means of the MTS-method, by exposing uninfected cells to the same concentrations of Favipiravir for 3 days. The % cell viability is calculated as (ODtreated/ODCC)×100, where ODCC is the OD of uninfected untreated cells and ODtreated are uninfected cells treated with compound. The CC50 is defined as the compound concentration that reduces the number of viable cells by 50%. The selectivity index (SI) is calculated as CC50/EC50[2]. |
Animal experiment: | Mice[1] Favipiravir (T 705) has also been shown to protect mice against lethal infection by a variety of influenza virus strains. When Favipiravir is orally administered 2 or 4 times a day for 5 days in mice infected with lethal doses of influenza virus A/Victoria/3/75(H3N2), A/Osaka/5/70(H3N2) or A/Duck/MN/1525/81(H5N1). |
References: [1]. Furuta Y, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446-54. | |
| Cas No. | 259793-96-9 | SDF | |
| Synonyms | Favilavir, Favipiravir | ||
| Chemical Name | 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide | ||
| Canonical SMILES | C1=C(N=C(C(=O)N1)C(=O)N)F | ||
| Formula | C5H4FN3O2 | M.Wt | 157.1 |
| Solubility | ≥ 6.2mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.3654 mL | 31.8269 mL | 63.6537 mL |
| 5 mM | 1.2731 mL | 6.3654 mL | 12.7307 mL |
| 10 mM | 0.6365 mL | 3.1827 mL | 6.3654 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *